Pluri (PLUR) Quality Rank


PLUR Pluri Inc PLUR
29 GF Score
Price $1.90
GF Value $6.51
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Pluri Quality Rank Related Terms

PLUR
29GF Score
Pluri Inc PLUR
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of $1.90 is trading 70.8% below its estimated GF Value™ of $6.51. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for PLUR:

  • Quality Rank:
  • GF Value™: $6.51 vs. price of $1.90 (70.8% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
29GF Score

Get the complete analysis for PLUR

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$6.51
GF Value